DoP clarifies on NPPA’s price-capping powers, under PMO supervision
According to DoP, it was brought to its notice that the NPPA has sought additional information — such as detailed agreement or contract between the manufacturer and marketer — from the applicant seeking price approval for new drugs under form-1 of DPCO, 2013.
DoP asks companies to revise MRP of drugs on which GST rates have been
The Department of Pharmaceuticals (DoP) has directed all the manufacturers and marketing companies to revise the maximum retail price (MRP) of drugs or formulations on which Goods and Services Tax (GST) has been reduced taking into effect the revised rates of GST.
DoP asks NPPA to review, verify Bharat Serum and Vaccine's request
The Department of Pharmaceuticals (DoP) has issued an order disposing the review application of Bharat Serum and Vaccine (BSVL) to the National Pharmaceutical Pricing Authority (NPPA) instructing to verify the applicability of GST factor by cross-checking the documents submitted by BSVL pertaining to the formulation Human Normal Immunoglobulin.
NPPA vs DoP | Current Affairs - IAS Parliament
The DoP, however, has said the National Pharmaceutical Pricing Policy, 2012, stipulates a decrease in ceiling prices if there is a reduction in the WPI, and the NPPA is expected to take action against companies selling drugs over that cap. As per DoP’s order, “It is the ceiling price that has to be changed in respect of a scheduled drug by
NEWSLETTER JUNE 2016 Inside this Issue
DoP asks NPPA to examine review applications filed by various pharma cos 6 IMS Health to conduct study on India joining global pharma 7 Govt plans strict enforcement of copyright law to tackle piracy 7 Who gains from the intellectual property rights policy? 8 INTA 2016: JPO reveals non-traditional trademarks boom 8
